Focus: Bel Air Pharmaceuticals is a newly founded (2024) specialty pharma company headquartered in Beverly Hills focused on diagnostics, wound care, and pain management with a neurology therapeutic area. The company operates a portfolio of legacy branded and generic medications with significant revenue concentration in a single product.
Profile data last refreshed 43m ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Bel Air Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Bel Air Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Bel Air Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Anchor product generating 60% of company revenue with 9-year patent protection; primary job security driver.
Second-largest revenue contributor facing imminent loss of exclusivity with no disclosed mitigation strategy.
Legacy hypertension product nearing exclusivity cliff with minimal disclosed Part D spending.
Niche antifungal prophylaxis product with LOE in 4 years; supports itraconazole franchise diversification.
4 discontinued, 8 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo